William Hartzel compensation by year
Emergent BioSolutions Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $466,970 |
| Bonus | $585,000 |
| Stock awards | $139,500 |
| Option awards | $187,175 |
| Non-equity incentive | $325,266 |
| Pension and deferred compensation | $0 |
| All other | $10,350 |
| Total | $1,714,261 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Emergent BioSolutions Inc. DEF 14A filed March 21, 2025, accession 0001367644-25-000080, and prior-year filings.
How this page was built: the Emergent BioSolutions Inc. filed document, accession 0001367644-25-000080. Every figure is read from that document and cited to the page and table it appears in. Filed March 21, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 15,000 | $143,400 | — |
| RSU | 8,205 | $78,440 | — |
| RSU | 6,154 | $58,832 | — |
| RSU | 3,074 | $29,387 | — |
| RSU | 2,222 | $21,242 | — |
| RSU | 2,051 | $19,608 | — |
| RSU | 1,971 | $18,843 | — |
| RSU | 1,539 | $14,713 | — |
| RSU | 1,538 | $14,703 | — |
| Option | 8,209 | — | $8.39 |
| Option | 2,052 | — | $11.66 |
| Option | 125,000 | — | $2.33 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Emergent BioSolutions Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
Insider transactions since the last proxy
11 Form 4 lines since the FY2024 proxy (filed March 21, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-08 | Tax withholding | — | 1,741 | $8.00 | 185,558 |
| 2026-04-29 | Grant or award | — | 100,111 | $0.00 | 187,299 |
| 2026-03-05 | Tax withholding | — | 9,493 | $8.44 | 87,188 |
| 2026-03-03 | Grant or award derivative | — | 44,834 | $0.00 | 259,545 |
| 2026-02-06 | Disposition to the issuer | — | 5,771 | $10.92 | 97,311 |
| 2026-02-06 | Tax withholding | — | 630 | $10.92 | 96,681 |
| 2025-11-11 | Tax withholding | — | 610 | $10.88 | 103,082 |
| 2025-07-11 | Tax withholding | — | 4,263 | $7.36 | 103,692 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Emergent BioSolutions’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Joseph Papa | President, Chief Executive Officer and Director | $5,862,562 |
| Richard Lindahl | Executive Vice President, Chief Financial Officer | $2,311,320 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $2,053,213 |
| William Hartzel · this page | Senior Vice President, Manufacturing and Bioservices | $1,714,261 |
| Paul Williams | Senior Vice President, Products Business | $1,675,687 |
| Jennifer Fox | Former Executive Vice President, External Affairs, General Counsel and Corporate Secretary | $1,189,933 |
| Haywood Miller | Former Interim Chief Executive Officer | $218,750 |
The full Emergent BioSolutions compensation record
free company briefThis page is one person within Emergent BioSolutions's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Emergent BioSolutions proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Emergent BioSolutions's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.